Understanding how CFTR affects lung function and diabetes in cystic fibrosis patients
Mechanisms linking CFTR to dysregulated barrier function, insulin receptor function, and glucose transport in the CF lung
This study is looking at how a protein called CFTR affects lung health and blood sugar control in people with cystic fibrosis, with the goal of finding new ways to improve treatment for those dealing with lung issues and diabetes related to the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11020351 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which the CFTR protein influences lung function and glucose regulation in patients with cystic fibrosis (CF). It focuses on how the loss of CFTR function leads to complications such as CF-related diabetes (CFRD) and worsens airway function. The study will explore the role of insulin signaling in both CF and non-CF airway cells, aiming to identify differences that could inform new treatment strategies. By examining the interactions between glucose transport and barrier function in the lungs, the research seeks to uncover critical insights into managing CF and its associated conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis, particularly those experiencing CF-related diabetes.
Not a fit: Patients without cystic fibrosis or those who do not have CF-related diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for lung function and diabetes management in cystic fibrosis patients.
How similar studies have performed: Previous research has shown promising results in understanding the role of CFTR in lung function and glucose metabolism, indicating that this approach has potential for significant advancements.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Mccarty, Nael a — Emory University
- Study coordinator: Mccarty, Nael a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.